# A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

> **NCT05274997** · PHASE2 · UNKNOWN · sponsor: **Shanghai YingLi Pharmaceutical Co. Ltd.** · enrollment: 97 (estimated)

## Conditions studied

- Peripheral T/NK Cell Lymphoma (R/R PTCL)

## Interventions

- **DRUG:** YY-20394

## Key facts

- **NCT ID:** NCT05274997
- **Lead sponsor:** Shanghai YingLi Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-01
- **Primary completion:** 2023-01-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 97 (ESTIMATED)
- **Last updated:** 2022-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05274997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05274997, "A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05274997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*